

# Pharmaceutical Pipeline – Key Events in 2021\*

## Potential Approvals US/EU

Amivantamab (EGFR/cMET)	– Non Small Cell Lung Cancer (US)
Ciltacabtagene Autoleucl (BCMA CAR-T)	– Multiple Myeloma (US)
DARZALEX®	– Amyloidosis (ANDROMEDA) (US ✓ / EU ) – Relapsed Refractory Multiple Myeloma w/PomDex (US / EU )
XARELTO®	– Infrainguinal revascular PAD (US) – Pediatric VTE (US)
SPRAVATO™ (esketamine nasal spray)	– Major Depressive Disorder with acute suicidal ideation or behavior (EU )
Paliperidone Palmitate 6-month	– Schizophrenia (US )
ponesimod	– Monotherapy for multiple sclerosis (US / EU )
CABENUVA® (rilpivrine Long Acting)	– HIV (US ✓)
UPTRAVI® IV	– Pulmonary arterial hypertension (US)
VAC31518	– Janssen COVID-19 Vaccine (US EUA, EU cMAA)

## Planned Submissions US/EU

Ciltacabtagene Autoleucl (BCMA CAR-T)	– Multiple Myeloma (US submission complete , EU )
Amivantamab (EGFR/cMET)	– Non Small Cell Lung Cancer (EU ✓)
IMBRUVICA®	– Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (US , EU )
XARELTO®	– Pediatric VTE (US)
VAC31518	– Janssen COVID-19 Vaccine (US EUA, EU cMAA)

## Potential Clinical Data Presentations

### Phase 3

STELARA®	– Crohn's Disease H2H vs. HUMIRA (SEAVUE)
Paliperidone Palmitate 6-month	– Schizophrenia (PSY3015)
IMBRUVICA®	– Frontline chronic lymphocytic leukemia (I+V fixed duration) (GLOW)
ERLEADA®	– Metastatic castrate sensitive prostate cancer- Final Analysis (TITAN)
XARELTO®	– COVID-19 MI (PREVENT-HD)

### Phase 2

Tesnatilamab (Anti-NKG2D)	– Crohn's Disease (TRIDENT)
Amivantamab (EGFR/cMET)	– 2L NSCLC (CHRYSALIS)

✓ = Achieved